Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$78.2 million.

  • Tg Therapeutics' Cash from Financing Activities fell 158.19% to -$78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.9 million, marking a year-over-year decrease of 171.96%. This contributed to the annual value of $128.5 million for FY2024, which is 76.78% up from last year.
  • Per Tg Therapeutics' latest filing, its Cash from Financing Activities stood at -$78.2 million for Q3 2025, which was down 1,114.37% from -$6.4 million recorded in Q2 2025.
  • Tg Therapeutics' Cash from Financing Activities' 5-year high stood at $134.5 million during Q3 2024, with a 5-year trough of -$78.2 million in Q3 2025.
  • Its 3-year average for Cash from Financing Activities is $10.0 million, with a median of $10,000 in 2024.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Financing Activities surged by 34,749.63% in 2023, and later plummeted by 607,100.00% in 2024.
  • Tg Therapeutics' Cash from Financing Activities (Quarterly) stood at $56.0 million in 2021, then plummeted by 99.91% to $49,000 in 2022, then plummeted by 102.04% to -$1,000 in 2023, then slumped by 607,100.00% to -$6.1 million in 2024, then tumbled by 158.19% to -$78.2 million in 2025.
  • Its last three reported values are -$78.2 million in Q3 2025, -$6.4 million for Q2 2025, and -$6.1 million during Q1 2025.